Todd Schlesinger, MD

Dr Todd Schlesinger | Image Credit: Epiphany Dermatology

Todd Schlesinger, MD, is the founder and director of the Dermatology & Laser Center of Charleston and the Clinical Research Center of the Carolinas.

Articles by Todd Schlesinger, MD

Balancing Efficacy and Tolerability in Skin Cancer Treatment: Todd Schlesinger, MD

ByBrooke McCormick,Pearl Steinzor,Todd Schlesinger, MD

April 3rd 2026

Proactive adverse effect management helps patients with skin cancer stay on treatment longer, according to Todd Schlesinger, MD.

Top Reasons Dermatologists Value the AAD 2026 Annual Meeting

ByPearl Steinzor,Melinda Gooderham, MD, MSc, FRCPC,April W. Armstrong, MD, MPH,Linda Stein Gold, MD,Joseph Lam, MD,Lauren Madigan, MD,Todd Schlesinger, MD

April 2nd 2026

Key session speakers and abstract presenters share their highlights of attending AAD 2026.

New Immunotherapy Advances and Multidisciplinary Care Strategies for Advanced Skin Cancer: Todd Schlesinger, MD

ByPearl Steinzor,Todd Schlesinger, MD

March 30th 2026

Todd Schlesinger, MD, discusses how new immunotherapies and multidisciplinary care are reshaping treatment approaches for patients with advanced skin cancers.

Q&A with Dr Todd Schlesinger | Image Credit: Epiphany Dermatology

Patients With cSCC Generally Tolerate Immunotherapies but Should Know About Common Adverse Events: Todd Schlesinger, MD

ByBrooke McCormick,Todd Schlesinger, MD

March 9th 2026

Clinicians must consider patient comorbidities and therapy safety when selecting immunotherapy for cSCC, says Todd Schlesinger, MD.

PD-1, PD-L1 Agents Improve Outcomes for Cutaneous Squamous Cell Carcinoma: Todd Schlesinger, MD

ByBrooke McCormick,Todd Schlesinger, MD

March 5th 2026

Immunotherapies are transforming treatment and improving outcomes for patients with advanced cSCC, according to Todd Schlesinger, MD.

Todd Schlesinger, MD

Articles by Todd Schlesinger, MD

Balancing Efficacy and Tolerability in Skin Cancer Treatment: Todd Schlesinger, MD

Top Reasons Dermatologists Value the AAD 2026 Annual Meeting

New Immunotherapy Advances and Multidisciplinary Care Strategies for Advanced Skin Cancer: Todd Schlesinger, MD

Patients With cSCC Generally Tolerate Immunotherapies but Should Know About Common Adverse Events: Todd Schlesinger, MD

PD-1, PD-L1 Agents Improve Outcomes for Cutaneous Squamous Cell Carcinoma: Todd Schlesinger, MD

Latest Updated Articles

Trending on AJMC

FDA Approves First Oral Carbapenem Antibiotic for Complicated UTIs

Oral COVID-19 PEP May Benefit High-Risk Groups More Than General Public: Peter J. Hotez, MD

Fourteen Years of HIV PrEP: How New Innovations Build on Decades of Progress in HIV

Study Finds Flaw in Method for Key Oncology Value-Based Care Model

Ontada Analysis Finds GLP-1 RA Use Linked to Improved Survival in Patients With Cancer